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Abstract
Background: The rs9939609 T>A single-nucleotide polymorphism (SNP) in the FTO gene has
previously been found to be associated with obesity in European Caucasian samples. The objective
of this study is to examine whether this association extends to metabolic syndrome (MetS) and
applies in non-Caucasian samples.
Methods: The FTO rs9939609 SNP was genotyped in 2121 subjects from four different non-
Caucasian geographical ancestries. Subjects were classified for the presence or absence of MetS
according to the International Diabetes Federation (IDF) and National Cholesterol Education
Program Adult Treatment Panel (NCEP ATP) III definitions.
Results: Carriers of ≥ 1 copy of the rs9939609 A allele were significantly more likely to have IDF-
defined MetS (35.8%) than non-carriers (31.2%), corresponding to a carrier odds ratio (OR) of 1.23
(95% confidence interval [CI] 1.01 to 1.50), with a similar trend for the NCEP ATP III-defined MetS.
Subgroup analysis showed that the association was particularly strong in men. The association was
related to a higher proportion of rs9939609 A allele carriers meeting the waist circumference
criterion; a higher proportion also met the HDL cholesterol criterion compared with wild-type
homozygotes.
Conclusion: Thus, the FTO rs9939609 SNP was associated with an increased risk for MetS in this
multi-ethnic sample, confirming that the association extends to non-Caucasian population samples.
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Background
The metabolic syndrome (MetS) is a clinical entity charac-
terized by abdominal obesity, hypertension, hypertriglyc-
eridemia, depressed plasma high-density lipoprotein
(HDL) cholesterol and elevated glucose [1,2]. MetS is
common, and will likely become even more pervasive,
considering the poor lifestyle habits prevalent in many
societies today. While the increased prevalence of MetS is
primarily related to an imbalance between caloric intake
and expenditure, genetic factors are also likely to be
important. Each defining component has been previously
associated with genetic factors, suggesting that genetic fac-
tors might underlie the overall MetS both independently
and through more complex interactions [3]. While the
precise definition of MetS is controversial, there is no
question that the MetS concept has proven to be valuable
clinically [4,5].
A potential candidate underlying genetic susceptibility to
MetS is the FTO (fat mass and obesity associated) gene,
encoding the human analogue of fused toes in mice. The
FTO  gene encodes a 2-oxoglutarate-dependent nucleic
acid demethylase that is present in many tissues, but most
abundant in the hypothalamus, the control center of
energy balance [6]. Studies in mice showing that Fto
mRNA levels are regulated by feeding and fasting have
provided a mechanistic link between FTO  and body
weight and energy homeostasis [6]. Human population
genetic studies have found FTO single nucleotide poly-
morphisms (SNPs) to be associated with type 2 diabetes
[7] and obesity [8-11]. The FTO rs9939609 SNP is of par-
ticular interest since it was found to be associated with
obesity through independent studies of large Caucasian
populations [8-11]. Since obesity is one of the key features
of MetS, we wondered whether this association signal
could be found with the complex trait of MetS and
whether the association could be detected across other
non-Caucasian populations. Thus, the purpose of this
study was to examine the FTO rs9939609 SNP as a poten-
tial genetic candidate for MetS, defined by both the
National Cholesterol Education Program Adult Treatment
Panel III (NCEP ATP III) and the International Diabetes
Federation (IDF) criteria, in a sample derived from multi-
ple non-Caucasian geographic ancestries.
Methods
Study subjects
The multi-ethnic study included Canadians of South
Asian and Chinese descent, Oji-Cree (Ontario, Canada),
and Inuit from Greenland. All subjects for the current
study were collected from one of the following popula-
tion studies: 1) the Study of Health Assessment and Risk
in Ethnic Groups [12]; 2) the Sandy Lake Health and Dia-
betes Project [13]; and 3) the Greenland Population Study
[14]. The details of these studies have been described pre-
viously [12-14]. Signed informed consent was obtained
from all participants and the study was approved by the
University of Western Ontario Ethics Review Board (pro-
tocol #7920E). For the current analysis, the number of
subjects ≥ 18 years of age with both sufficient DNA for
FTO genotype determination and a complete set of data
for MetS diagnosis included 325 South Asians, 299 Chi-
nese, 400 Oji-Cree, and 1097 Greenland Inuit; a total of
2121 subjects (53.9% female). There was no exclusion
based on diabetes status.
Physical measurements
Measurements of waist circumference, blood pressure,
fasting analytes, including venous plasma glucose, serum
cholesterol, triglycerides (TG), low-density lipoprotein
(LDL) cholesterol, and HDL cholesterol were performed
as described [12-14].
Metabolic syndrome classification
According to the NCEP ATP III criteria [1], MetS was iden-
tified if a subject had ≥ 3 of: 1) increased waist circumfer-
ence (>102 cm [>40 inches] for men, >88 cm [>35 inches]
for women); 2) elevated plasma TG (≥ 1.69 mmol/L [≥
150 mg/dL]); 3) low plasma HDL cholesterol (<1.04
mmol/L [<40 mg/dL] for men, <1.29 mmol/L [<50 mg/
dL] for women); 4) hypertension (≥ 130/≥ 85 mmHg) or
current medication; or 5) impaired fasting glucose (≥ 6.1
mmol/L [≥ 110 mg/dL]).
The IDF criteria [15] identifies MetS for subjects with cen-
tral obesity, according to ethnic specific guidelines (waist
circumference for South Asians and Chinese ≥ 90 cm for
men, ≥ 80 cm for women), plus any two of: 1) elevated
plasma TG (≥ 1.69 mmol/L [≥ 150 mg/dL]); 2) low
plasma HDL cholesterol (<1.04 mmol/L [<40 mg/dL] for
men, <1.29 mmol/L [<50 mg/dL] for women); 3) hyper-
tension (≥ 130/≥ 85 mmHg) or current medication; or 4)
impaired fasting glucose (≥ 5.6 mmol/L [≥ 100 mg/dL]) or
previously diagnosed type 2 diabetes. Since no quantita-
tive thresholds exist yet for aboriginal populations, these
subjects were also evaluated using the South Asian and
Chinese threshold values for waist circumference.
Genotyping of the FTO polymorphism
Detection of the FTO  SNP rs9939609 was carried out
using a validated TaqMan genotyping assay (Assay ID
C_25638153_10; Applied Biosystems, Foster City, CA).
SNP genotyping was performed using an allelic discrimi-
nation assay (TaqMan® SNP Genotyping Assays, Applied
Biosystems, Foster City, CA) using the 7900HT Fast Real-
Time PCR System and genotypes were read using auto-
mated software (SDS 2.3, Applied Biosystems, Foster City,
CA). Reactions were run in 5 µL volumes using an ampli-
fication protocol of 95°C for 10 minutes, followed by 50
cycles of 95°C for 15 seconds, then 60°C for 1.5 minutes.Cardiovascular Diabetology 2008, 7:5 http://www.cardiab.com/content/7/1/5
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Statistical analysis
SAS version 9.1 (SAS Institute, Cary, NC) was used for all
statistical comparisons. Data are presented as means ±
standard deviation (SD) or as percentages for discrete var-
iables. Between-group differences in discrete variables
were analyzed using χ2 analysis and odds ratios (OR) were
calculated using the "case-control" method in the FREQ
procedure in SAS. Differences in quantitative traits were
analyzed by ANOVA, using the general linear model,
adjusted for age. The significance of deviations of
observed genotype frequencies from those predicted by
the Hardy-Weinberg equation were evaluated with χ2
tests. The rs9939609 T>A genotypes were included in the
analysis as a dichotomous variable, in both dominant and
recessive models. Statistical significance was taken at a P-
value<0.05 for all comparisons.
Results
Table 1 shows the demographic and metabolic character-
istics of the populations included in the study. The FTO
rs9939609 A allele frequencies were 0.32, 0.12, 0.066,
and 0.18, for the South Asians, Chinese, Oji-Cree, and
Greenland Inuit, respectively. The genotype frequencies
did not deviate from the Hardy-Weinberg predictions
(data not shown).
Analysis across the 4 study populations indicated that
FTO rs9939609 A allele carriers had an increased risk of
MetS, according to the IDF definition (carrier OR 1.23,
95% CI 1.01 to 1.50, P = 0.036) (Table 2). Subgroup anal-
ysis of females showed that the carrier OR was 1.05 (95%
CI 0.80 to 1.38, P  = NS [0.74]). Subgroup analysis of
males showed that the carrier OR was 1.46 (95% CI 1.10
to 1.94, P = 0.0081). By individual ethnic populations, a
significant increased risk for MetS was observed for FTO
rs9939609 A allele carriers only in the South Asian group
(P = 0.027). Analysis of the NCEP ATP III definition for
MetS showed a similar trend towards increased risk for
FTO rs9939609 A allele carriers compared to TT homozy-
gotes (carrier OR 1.26, 95% CI 1.02 to 1.57, P = 0.036)
(Table 2). A significant increased risk for NCEP ATP III
MetS was observed for FTO rs9939609 A allele carriers
among Greenland Inuit (P = 0.037).
No significant increased risk of MetS was observed overall
for AA homozygotes, for either the IDF or NCEP ATP III
definitions, upon repeating the analyses using a recessive
model for the FTO rs9939609 A allele. The non-signifi-
cant trends suggested that sample numbers were insuffi-
cient for detecting an association with this particular trait.
Analysis of the entire sample revealed no significant
increase in blood pressure, plasma triglycerides or glucose
levels (Table 2). However, meta-analysis indicated that
significantly more FTO rs9939609 A allele carriers met the
Table 1: Clinical and biochemical data of subjects
Male Female P-value
Greenland Inuit n = 486 n = 622
age (years) 46.2 ± 12.9 45.8 ± 13.1 NS (0.60)
BMI (kg/m2) 26.2 ± 4.6 26.7 ± 5.42 NS (0.072)
waist (cm) 91.1 ± 12.2 88.1 ± 13.5 0.0001
systolic BP (mmHg) 120 ± 17 119 ± 20 NS (0.14)
diastolic BP (mmHg) 74 ± 11 72 ± 11 <0.0001
total cholesterol (mmol/L) 5.99 ± 1.18 6.02 ± 1.13 NS (0.77)
triglycerides (mmol/L) 1.15 ± 0.66 1.12 ± 0.61 NS (0.090)
LDL cholesterol (mmol/L) 3.90 ± 1.091 3.89 ± 1.062 NS (0.67)
HDL cholesterol (mmol/L) 1.56 ± 0.49 1.62 ± 0.42 0.0015
fasting glucose (mmol/L) 5.83 ± 0.89 5.76 ± 1.34 NS (0.21)
MetS (%) 12.1 17.0 0.017
Oji-Cree n = 218 n = 291
age (years) 35.9 ± 14.5 35.7 ± 14.7 NS (0.85)
BMI (kg/m2) 26.8 ± 4.6 29.1 ± 5.5 <0.0001
waist (cm) 96.9 ± 12.2 95.0 ± 11.9 NS (0.073)
systolic BP (mmHg) 122 ± 14 118 ± 16 <0.0001
diastolic BP (mmHg) 70 ± 12 67 ± 10 <0.0001
total cholesterol (mmol/L) 4.83 ± 0.98 4.59 ± 0.82 0.0001
triglycerides (mmol/L) 1.63 ± 0.85 1.51 ± 0.71 0.0003
LDL cholesterol (mmol/L) 2.91 ± 0.823 2.62 ± 0.654 <0.0001
HDL cholesterol (mmol/L) 1.19 ± 0.30 1.28 ± 0.28 <0.0001
fasting glucose (mmol/L) 6.73 ± 3.25 6.77 ± 3.50 NS (0.61)
MetS (%) 30.3 39.2 0.028
South Asian n = 180 n = 147
age (years) 49.9 ± 8.9 49.0 ± 9.6 NS (0.37)
BMI (kg/m2) 26.1 ± 4.35 26.5 ± 3.8 NS (0.37)
waist (cm) 94.7 ± 9.7 86.0 ± 10.6 <0.0001
systolic BP (mmHg) 121 ± 16 117 ± 19 0.034
diastolic BP (mmHg) 80 ± 12 71 ± 10 <0.0001
total cholesterol (mmol/L) 5.26 ± 0.98 5.15 ± 0.94 NS (0.41)
triglycerides (mmol/L) 2.05 ± 1.31 1.92 ± 1.27 NS (0.30)
LDL cholesterol (mmol/L) 3.45 ± 0.846 3.18 ± 0.797 0.0069
HDL cholesterol (mmol/L) 0.95 ± 0.26 1.13 ± 0.32 <0.0001
fasting glucose (mmol/L) 5.95 ± 1.89 5.49 ± 1.58 0.020
MetS (%) 31.1 34.0 NS (0.38)
Chinese n = 148 n = 151
age (years) 48.8 ± 9.3 46.6 ± 8.4 0.030
BMI (kg/m2) 25.2 ± 3.4 22.7 ± 3.5 <0.0001
waist (cm) 89.6 ± 9.1 75.2 ± 7.9 <0.0001
systolic BP (mmHg) 122 ± 17 112 ± 20 0.022
diastolic BP (mmHg) 80 ± 10 70 ± 12 <0.0001
total cholesterol (mmol/L) 5.29 ± 1.00 4.85 ± 0.84 0.0057
triglycerides (mmol/L) 2.14 ± 1.61 1.38 ± 1.03 0.0055
LDL cholesterol (mmol/L) 3.34 ± 0.848 2.90 ± 0.719 0.0006
HDL cholesterol (mmol/L) 1.03 ± 0.29 1.33 ± 0.36 <0.0001
fasting glucose (mmol/L) 5.44 ± 1.29 4.98 ± 0.60 0.016
MetS (%) 28.4 10.6 0.0003
1n = 483, 2n = 620, 3n = 216, 4n = 289, 5n = 179, 6n = 169, 7n = 141, 8n = 139, 9n = 
148
Abbreviations: BMI, body mass index; BP, blood pressure; LDL, low-density 
lipoprotein; HDL, high-density lipoprotein; MetS, metabolic syndrome; NS, not 
significant.
Data are means ± standard deviation (SD). P-values are adjusted for age; P-values 
for blood pressure, cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, 
and glucose are also adjusted for BMI.Cardiovascular Diabetology 2008, 7:5 http://www.cardiab.com/content/7/1/5
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Table 2: Metabolic syndrome and metabolic syndrome component prevalence in subjects when classified in accordance to their 
genotype of the FTO rs9939609 T>A polymorphism
TT AA & AT OR (95% CI) P-value
Overall N = 2121 1482 639
IDF MetS (%) 31.2 35.8 1.23 (1.01, 1.50) 0.036
South Asian 36.8 49.1 1.66 (1.06, 2.58) 0.027
Chinese 24.6 22.4 0.89 (0.46, 1.69) 0.71
Oji-Cree 48.9 51.9 1.13 (0.63, 2.03) 0.68
Greenland Inuit 23.9 29.4 1.33 (0.99, 1.77) 0.051
NCEP ATP III MetS (%) 21.1 25.2 1.26 (1.02, 1.57) 0.036
South Asian 28.3 35.8 1.42 (0.88, 2.27) 0.15
Chinese 18.5 22.4 1.27 (0.65, 2.46) 0.48
Oji-Cree 36.2 40.4 1.19 (0.66, 2.17) 0.56
Greenland Inuit 13.3 18.2 1.44 (1.02, 2.04) 0.037
MetS BP (%) 30.3 33.2 1.14 (0.94, 1.39) 0.19
South Asian 35.5 33.0 0.89 (0.56, 1.41) 0.62
Chinese 32.8 40.3 1.39 (0.79, 2.43) 0.25
Oji-Cree 27.6 19.2 0.63 (0.30, 1.30) 0.20
Greenland Inuit 29.7 34.0 1.22 (0.93, 1.60) 0.16
MetS Triglycerides (%) 25.0 26.5 1.08 (0.87, 1.34) 0.47
South Asian 46.1 46.8 1.03 (0.67, 1.60) 0.89
Chinese 38.8 31.3 0.72 (0.40, 1.29) 0.27
Oji-Cree 33.1 40.4 1.37 (0.76, 2.49) 0.30
Greenland Inuit 12.7 13.3 1.05 (0.72, 1.54) 0.79
MetS HDL (%) 33.7 39.6 1.29 (1.07, 1.56) 0.0089
South Asian 69.1 71.7 1.13 (0.70, 1.83) 0.61
Chinese 51.7 61.2 1.47 (0.85, 2.56) 0.17
Oji-Cree 45.7 59.6 1.75 (0.97, 3.17) 0.061
Greenland Inuit 15.3 16.4 1.09 (0.77, 1.53) 0.64
MetS Glucose (%) 45.3 47.7 1.10 (0.92, 1.33) 0.30
South Asian 25.7 34.1 1.50 (0.93, 2.43) 0.098
Chinese 17.2 20.9 1.27 (0.64, 2.50) 0.49
Oji-Cree 53.5 44.2 0.69 (0.38, 1.24) 0.21
Greenland Inuit 54.1 60.2 1.28 (0.99, 1.66) 0.059
MetS Waist (IDF) (%) 60.9 65.0 1.19 (0.98, 1.44) 0.080
South Asian 64.5 75.1 1.67 (1.03, 2.69) 0.036
Chinese 34.9 32.8 0.91 (0.51, 1.62) 0.75
Oji-Cree 81.0 78.9 0.87 (0.43, 1.79) 0.71
Greenland Inuit 58.9 64.0 1.24 (0.95, 1.61) 0.11
BMI>33 kg/m2 (%) 8.1 10.6 1.35 (0.99, 1.84) 0.060
South Asian 4.0 5.8 1.48 (0.53, 4.18) 0.45
Chinese 2.2 1.5 0.69 (0.079, 5.99) 0.73
Oji-Cree 13.5 26.9 2.36 (1.19, 4.68) 0.012
Greenland Inuit 8.3 12.4 1.57 (1.04, 2.36) 0.032Cardiovascular Diabetology 2008, 7:5 http://www.cardiab.com/content/7/1/5
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MetS criteria for depressed HDL cholesterol (P = 0.0089),
and there was a nonsignificant trend towards increased
waist circumference and increased BMI for FTO
rs9939609 A allele carriers (P = 0.080 and 0.060, respec-
tively) (Table 2).
Discussion
Our study of FTO as a candidate gene for MetS in a sample
from multiple non-Caucasian geographical ancestries
showed 1) significant association with the FTO gene, with
rs9939609 A allele carriers, particularly males, having an
increased risk of MetS (carrier OR 1.23, 95% CI 1.01 to
1.50; P = 0.036) (Table 2); and 2) this association was
related to higher proportion of subjects with depressed
HDL cholesterol and a trend towards increased waist cir-
cumference. Similar trends were observed for the NCEP
ATP III definition of MetS.
This is the first report of an association between the FTO
rs9939609 A allele and MetS. Furthermore, it extends the
association of this allele beyond Caucasian samples.
Although the observation may help understand the
molecular etiology of MetS, this association requires rep-
lication in larger studies, considering the possibility of a
spurious association due to population stratification or
another such limitation [16]. Despite considerations
regarding sample size however, the results reaffirm the
established association between the FTO  rs9939609 A
allele with obesity in past findings [8-11]. However, MetS
is a complex disorder, and only a few of the previously
associated genes, such as APOC3 and PPARG, have been
replicated in more than one study sample [4]. Aside from
the need to replicate the FTO association in other larger
study samples, the mechanism underlying the association
also needs to be investigated. The mechanism underlying
the association may be related to: 1) a direct function of
FTO [6] or 2) linkage disequilibrium of the tested variant
with another causative change in a gene near the FTO
locus.
Analysis of the overall sample indicated that significantly
more FTO rs9939609 A allele carriers met the MetS criteria
for depressed HDL cholesterol (P = 0.0089) than non-car-
riers. In addition, values were close to significance also for
increased waist circumference (P = 0.080) and increased
BMI (P = 0.060) among A allele carriers (Table 2). This
indicates that the association of the FTO  rs9939609 A
allele with the MetS was related in part to both the obesity
component, but also the HDL component, suggesting that
this genetic marker may have a broader relationship with
individual components of this complex trait.
Although the meta-analysis across the four non-Caucasian
study populations showed an association between MetS
and the common rs9939609 SNP in FTO, analyses by
individual ethnic populations indicated a significant
increased risk for MetS only among the South Asians (IDF
definition) and Greenland Inuit (NCEP ATP III defini-
tion). Thus, the overall association is primarily due to
these two populations, with little influence from the Chi-
nese and Oji-Cree. Again, replication of the FTO associa-
tion in other larger study samples is essential for
clarification. Further evidence against an association for
the Chinese can be found in a recent study of 3,210 unre-
lated Chinese Han subjects from Shanghai and Beijing
where no association found between the rs9939609 SNP
and obesity [17].
In summary, we report an association between MetS and
the common rs9939609 SNP in FTO. The observed con-
sistent association between MetS and FTO in a non-Cau-
casian multi-ethnic study group, including populations
which differ considerably in MetS prevalence, strengthens
the likelihood that the FTO locus is related to obesity and
MetS. Future replication of this association in larger sized
samples and devising functional molecular studies will
further enhance the validity of association and the causa-
tive relationship between the FTO variant and MetS.
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